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Tissue engineering of functional trileaflet heart valves from
human marrow stromal cells
Abstract
BACKGROUND: We previously demonstrated the successful tissue engineering and implantation of
functioning autologous heart valves based on vascular-derived cells. Human marrow stromal cells
(MSC) exhibit the potential to differentiate into multiple cell-lineages and can be easily obtained
clinically. The feasibility of creating tissue engineered heart valves (TEHV) from MSC as an alternative
cell source, and the impact of a biomimetic in vitro environment on tissue differentiation was
investigated. METHODS AND RESULTS: Human MSC were isolated, expanded in culture, and
characterized by flow-cytometry and immunohistochemistry. Trileaflet heart valves fabricated from
rapidly bioabsorbable polymers were seeded with MSC and grown in vitro in a
pulsatile-flow-bioreactor. Morphological characterization included histology and electron microscopy
(EM). Extracellular matrix (ECM)-formation was analyzed by immunohistochemistry, ECM protein
content (collagen, glycosaminoglycan) and cell proliferation (DNA) were biochemically quantified.
Biomechanical evaluation was performed using Instron(TM). In all valves synchronous opening and
closing was observed in the bioreactor. Flow-cytometry of MSC pre-seeding was positive for ASMA,
vimentin, negative for CD 31, LDL, CD 14. Histology of the TEHV-leaflets demonstrated viable tissue
and ECM formation. EM demonstrated cell elements typical of viable, secretionally active
myofibroblasts (actin/myosin filaments, collagen fibrils, elastin) and confluent, homogenous tissue
surfaces. Collagen types I, III, ASMA, and vimentin were detected in the TEHV-leaflets. Mechanical
properties of the TEHV-leaflets were comparable to native tissue. CONCLUSION: Generation of
functional TEHV from human MSC was feasible utilizing a biomimetic in vitro environment. The
neo-tissue showed morphological features and mechanical properties of human native-heart-valve
tissue. The human MSC demonstrated characteristics of myofibroblast differentiation.
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Tissue Engineering of Functional Trileaflet Heart Valves
From Human Marrow Stromal Cells
Simon P. Hoerstrup, MD; Alexander Kadner, MD; Serguei Melnitchouk, MD; Andreas Trojan, MD;
Karim Eid, MD; Jay Tracy, Ralf Sodian, MD; Jeroen F. Visjager, PhD; Stefan A. Kolb, MD;
Jurg Grunenfelder, MD; Gregor Zund, MD; Marko I. Turina, MD
Background—We previously demonstrated the successful tissue engineering and implantation of functioning autologous
heart valves based on vascular-derived cells. Human marrow stromal cells (MSC) exhibit the potential to differentiate
into multiple cell-lineages and can be easily obtained clinically. The feasibility of creating tissue engineered heart valves
(TEHV) from MSC as an alternative cell source, and the impact of a biomimetic in vitro environment on tissue
differentiation was investigated.
Methods and Results—Human MSC were isolated, expanded in culture, and characterized by flow-cytometry and
immunohistochemistry. Trileaflet heart valves fabricated from rapidly bioabsorbable polymers were seeded with MSC
and grown in vitro in a pulsatile-flow-bioreactor. Morphological characterization included histology and electron
microscopy (EM). Extracellular matrix (ECM)-formation was analyzed by immunohistochemistry, ECM protein content
(collagen, glycosaminoglycan) and cell proliferation (DNA) were biochemically quantified. Biomechanical evaluation
was performed using Instron™. In all valves synchronous opening and closing was observed in the bioreactor.
Flow-cytometry of MSC pre-seeding was positive for ASMA, vimentin, negative for CD 31, LDL, CD 14. Histology
of the TEHV-leaflets demonstrated viable tissue and ECM formation. EM demonstrated cell elements typical of viable,
secretionally active myofibroblasts (actin/myosin filaments, collagen fibrils, elastin) and confluent, homogenous tissue
surfaces. Collagen types I, III, ASMA, and vimentin were detected in the TEHV-leaflets. Mechanical properties of the
TEHV-leaflets were comparable to native tissue.
Conclusion—Generation of functional TEHV from human MSC was feasible utilizing a biomimetic in vitro environment.
The neo-tissue showed morphological features and mechanical properties of human native-heart-valve tissue. The
human MSC demonstrated characteristics of myofibroblast differentiation. (Circulation. 2002;106[suppl I]:I-143-I-150.)
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Current options of surgical heart valve replacement com-prising of mechanical or biological prostheses substan-
tially changed the natural history of end-stage valvular heart
disease.1 Unfortunately, there are limitations as to the long
term benefits of clinically available valve prostheses.2 Me-
chanical valves are associated with a significant risk of
thromboembolism,3 and biological valves suffer from struc-
tural dysfunction because of progressive tissue deterioration.4
Contemporary clinically available valve prostheses basically
represent nonviable structures and lack the potential to grow,
to repair, or to remodel.5
Tissue engineering represents a novel scientific concept to
overcome these limitations aiming at in vitro fabrication of
living heart valves with a thromboresistant surface and a
viable interstitium with repair and remodeling capabilities.
Several groups demonstrated the feasibility of creating living
cardiovascular structures by cell seeding on synthetic poly-
mer, collagen, or xenogenic scaffold.6–9 However, limitations
of these tissue engineered constructs included structural
immaturity and sub-optimal mechanical properties resulting
in unfavorable in vivo results.10 Recently our group demon-
strated the first successful tissue engineering of a completely
autologous, living tissue engineered heart valve (TEHV) in a
juvenile sheep model.11 These TEHV showed excellent func-
tional performance up to 20 weeks and strongly resembled
natural heart valves as to microstructure, biomechanical
profile and matrix protein formation. Up to now, most
approaches were based on the utilization of vascular derived
cells associated with certain shortcomings. Cell harvesting
before seeding necessitated the sacrifice of intact vascular
structures of the donor organism. Apart from that, vascular
derived cells demonstrated different characteristics compared
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with natural valvular interstitial cells, qualities which might be
vital to the development and long term function of TEHV.12
In search for alternative cell sources, especially with regard
to future routine clinical realization of the tissue engineering
concept, we identified human marrow stromal cells (MSC) as
a promising candidate. The usage of MSC may offer several
advantages in 1) easy collection by a simple bone marrow
puncture avoiding the sacrifice of intact vascular structures,
2) showing the potential to differentiate into multiple cell
lineages, and 3) demonstrating unique immunological char-
acteristics allowing persistence in allogenic settings.13,14
In the present study we investigated the feasibility of
creating functional tissue engineered heart valves on the basis
of human MSC and the influence of a biomimetic in vitro
environment on tissue formation and cell differentiation.
Methods
Bioabsorbable Trileaflet Valve Scaffold
Nonwoven polyglycolic-acid mesh (PGA, thickness: 1.0 mm, spe-
cific gravity: 69 mgcm3, Albany Int.) was coated with a thin layer of
poly 4-hydroxybutyrate (P4HB, MW: 1106, Tepha Inc., Cam-
bridge, MA) by dipping into a tetrahydrofuran solution (1% wt/vol
P4HB). Following solvent evaporation, a continuous coating and
physical bonding of adjacent fibers was achieved. P4HB is a
biologically derived rapidly absorbable biopolymer which is strong,
pliable, and thermoplastic (Tm 61°C) so it can be molded into almost
any shape. Complete biodegradation of the combined material occurs
after 4 to 6 weeks. From the PGA/P4HB composite scaffold material
trileaflet heart valve scaffolds were fabricated using a heat applica-
tion welding technique. The constructs were then cold gas sterilized
with ethylene oxide.
Cell Isolation and Cultivation
Human MSC were obtained by bone marrow punctures (iliac crest)
from healthy individuals (n5, mean age 355 years) after in-
formed consent was obtained from each participant. Human MSC
were isolated from 10–15 mL of bone marrow aspirate and resus-
pended in 20 mL Dulbecco’s modified Eagle’s medium (DMEM,
Gibco) supplemented with 10% fetal bovine serum (HyClone),
penicillin (Gibco), streptomycin (Gibco), and 1000 U heparin (Roche
Pharma AG, Reinach, Switzerland). Following the cell suspension
was centrifuged over a Ficoll step gradient (density 1.077 g/mL)
(Ficoll-Histopaque 1077, Sigma) at 1500 rpm for 10 minute. The
interface fraction was collected and cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal
bovine serum (HyClone), penicillin (Gibco), streptomycin (Gibco),
in tissue flasks (Corning, Inc). The nonadherent cells floated off
while MSC adhered, spread, and grew. Medium was replaced at 24
and 72 hours and every 6 days following. Cells were serially
passaged and expanded in a humidified incubator at 37°C with 5%
CO2. Sufficient cell numbers for cell seeding on bioabsorbable
polymer scaffolds were obtained after 21–28 days.
Cell Seeding and In Vitro Culture
Purified human MSC (4.5 to 5.5106 per cm2) were seeded onto the
trileaflet valve scaffolds and cultured in static nutrient medium
(DMEM, Gibco) for 7 days in a humidified incubator (37°C, 5%
CO2). Two groups of seeded heart valve constructs were investi-
gated. In group A, the constructs (n5) were transferred into a pulse
duplicator system (“bioreactor”) and grown under gradually increas-
ing nutrient media flow and pressure conditions for additional 14
days (125 mL/min at 30 mm Hg (days 1 to 4); 250 mL/min at
40 mm Hg (days 5 to 7); 500 mL/min at 50 mm Hg (days 8 to 10);
750 mL/min at 75 mm Hg (days 11 to 14)). In group B (controls,
n5) the seeded heart valve constructs were grown in static nutrient
media (absence of pulsed nutrient media flow) accordingly. The
media was changed every 4 days.
Analysis of MSC Cultures and Trileaflet TEHV
Flow Cytometry
A single cell suspension of 0.5 to 1106 MSC in 100 L PBS was
incubated with saturating concentrations of monoclonal antibodies
CD 31-FITC (Sigma, St. Louis), LDL-Dil (Biomedical Technologies
Inc, Stoughton, MA), CD 14-FITC (Beckon Dickinson, San Jose,
CA). For intracellular staining, cells were permeabilized with ethanol
for 30 minute and incubated with monoclonal antibodies against
ASMA (Sigma, St. Louis) and vimentin (NeoMarkers, Fremont).
After washing, staining with a secondary FITC-conjugated IgG
goat-anti-mouse antibody (Chemicon, Temecula, CA) was per-
formed for 30 minute. Forward and side scatter gates were set to
exclude debris and 10 000 gated events were counted per sample.
Corresponding isotype and positive controls were performed for each
antibody. Cells were analyzed with the flow cytometer FACS-
Calibur (Becton Dickinson Immunocytometry Systems, San Jose,
CA) and data were analyzed with the CELL QUEST software
program (Becton Dickinson Immunocytometry Systems, San Jose,
CA). Expression levels were calculated as mean fluorescence inten-
sity ratio (MFIR) defined as mean fluorescence intensity of the
studied antibodies divided by mean fluorescence intensity of corre-
sponding isotype controls.
Histology and Immunohistochemistry
MSC cultivated onto glass coverslips were examined histologically
by hematoxylin and eosin (H&E) and Trichrome-masson staining. In
addition, immunohistochemistry was performed by incubation with
monoclonal mouse antibodies for ASMA (Sigma, St. Louis), vimen-
tin (NeoMarkers, Fremont), desmin (NeoMarkers, Fremont), colla-
gen I, II, III, IV (Oncogen, Boston), and elastin (Sigma, St. Louis).
After incubation with a secondary biotin-labeled goat-anti-mouse
IgG antibody (Sigma, St. Louis) the signal was developed with the
avidin-peroxidase system (ABC kit, Vector Laboratory, Burlingame
CA). Before intracellular staining, permeabilization of the cells was
performed by incubation with 0.1% Triton (Sigma, St. Louis) for 10
minute. A representative portion of each valve construct was
examined histologically by H&E stain (overall morphology), and
Trichrome-Masson stain (for demonstration of matrix elements,
including collagen, elastin, glycosaminoglycans). Immunhistochem-
istry was performed on frozen and paraffin embedded valve and
Figure 1. Isolated MSC appeared small and rounded with a ten-
dency to grow in clusters. Elongated cells with fibroblast-like
morphology appeared after 72 hours and reached confluence
after 10–14 days (Figs. 1a and b). Fluorescence immunohisto-
chemistry of the cultivated MSC showed positive staining for
ASMA (Fig. 1c) and vimentin (Fig. 1d).
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static control sections. Tissue sections were stained using standard
indirect immunoperoxidase avidin-biotin or immunofluorescence
(FITC) techniques with monoclonal antibodies for -smooth muscle
actin (ASMA, Sigma, St. Louis), vimentin (NeoMarkers, Fremont),
desmin (NeoMarkers, Fremont) as well as collagen I, II, III, IV
(Oncogene, Boston) and elastin (Sigma, St. Louis).
Scanning and Transmission Electron Microscopy
Samples of each trileaflet valve construct were fixed in 2% glutar-
aldehyde (Sigma, St. Louis) for scanning electron microscopy (SEM)
and transmission electron microscopy (TEM).
Quantitative Biochemical Matrix Analysis
As described previously, biochemical assays for total content of
DNA, hydroxyprolin, proteoglycan/glycosaminoglycan (GAG)
(BLYSCAN™ assay, Biocolor, Belfast, Ireland), and elastin (FAS-
TIN™ assay, Biocolor, Belfast, Ireland) were performed and com-
pared with native human tissue (semilunar valve).11
Mechanical Properties
Tissue engineered valve leaflet constructs and human native tissue
valves were analyzed for mechanical properties by using a mechan-
Figure 2. Flow cytometry analysis of MSC demonstrated no significant
difference in the expression of ASMA (black) and vimentin (black) com-
pared with vascular myofibroblasts (gray). No positive signals were
detected for LDL (black) and CD31 (black) compared with endothelial
cells (gray), and CD14 (black) compared with peripheral blood mononu-
clear cells (gray).
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ical tester (Instron, Instron Corp., Canton, MA). Longitudinal matrix
strips were used for the test. A 75 psig maximum load cell was used
and the cross head speed was 0.5 inch per minute. The Young’s
modulus was obtained from the slope of the initial linear section of
the stress-strain curve.
Statistics
Result data were expressed as mean  standard error of the mean.
We used SPSS 8.0 software for statistical analysis. An unpaired t test
(Student’s t test) was performed, considering a P0.05 as
statistically significant.
Results
Analysis of Isolated MSC
Morphology of the isolated cells initially appeared small and
rounded with a tendency to grow in clusters. Nonadherent
cells were removed by medium change at 24 hours and every
4 days thereafter. Elongated cells with fibroblast-like mor-
phology appeared after 72 hours and reached confluence after
10–14 days (Figure 1a, b).
Immunohistochemistry of fixed cells showed the expres-
sion of ASMA and vimentin (Figure 1c, d). Staining for the
deposition of collagen I and III showed positive signals. In
contrast, no signal was observed following antibody staining
for desmin, collagen II, IV, and elastin.
Flow Cytometry analysis of MSC demonstrates no signif-
icant difference in the expression of ASMA (MFIR 3.66) and
vimentin (MFIR 12.59) compared with vascular-derived
myofibroblasts. No positive signal was detected for CD 14
(MFIR 1.13), CD 31 (MFIR 1.1), and LDL (MFIR 1.94)
among the isolated cell population (Figure 2).
Analysis of MSC-Based TEHV
In all TEHV a synchronous opening and closing of the
leaflets was observed in the bioreactor. Before explantation
form the pulse duplicator at day 14, the TEHV was tested in
the transparent system under both low (0.125 L/min at
30 mm Hg for 60 minute) and high flow and pressure
conditions (4.5 L/min at 200 mm Hg for 60 minute). Gross
Figure 3. Function of the TEHV in the pulse duplicator in vitro
system (bioreactor; view from above on TEHV positioned in flow
perfusion chamber). Note the TEHV in closed (Fig. 3a), interme-
diate (Fig. 3b), and fully opened position (Fig. 3c).
Figure 4. MSC based tissue engineered heart valve after 14
days in the pulse duplicator in vitro system (bioreactor). Note
the thin (0.4 to 0.6 mm), intact, pliable 3 leaflets.
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appearance showed that all leaflets were intact, mobile, and
pliable and the valve constructs were competent during valve
closure (Figures 3 and 4).
Histology and Immunhistochemistry of TEHV
H&E and Trichrome-masson staining of representative
TEHV leaflet sections demonstrated cellular tissue organized
in a layered fashion with a dense outer layer and lesser
cellularity in the deeper portions after 14 days in the pulse
duplicator. Immunohistochemistry showed positive staining
for collagen types I, III, -SMA, and vimentin. No positive
staining was observed for desmin, collagen types II and IV.
Static controls showed a loose, less organized tissue forma-
tion with irregular cellular ingrowth (Figure 5).
Transmission and Scanning Microscopy
TEM revealed cell elements typical of viable, secretionally
active myofibroblasts such as actin/myosin filaments as well
as collagen fibrils and elastin fiber networks. SEM showed
dense tissue formation and a confluent smooth surface with
cell orientation in flow direction. Advanced biodegradation of
the polymer scaffold was detected by multiple hydrolytic
breakage and fragmentation of the polymer fibers. In contrast,
SEM analysis of static controls showed a nonconfluent and
less homogeneous surface (Figure 6).
Quantitative Biochemical Assays
The results of the quantitative biochemical assays are sum-
marized in Figure 7. The extracellular matrix proteins of the
TEHV showed significantly lower values compared with
human native heart valve tissue (P0.05). Collagen (hy-
droxyproline) content reached 25% and glycosaminoglycan
content 37% that of the native human controls. There was no
elastin detectable in the TEHV constructs. DNA content of
the TEHV was significantly higher (P0.01) compared with
human native heart valve tissue reaching value of300%.
Mechanical Properties
The biomechanical profile of the MSC-TEHV leaflets was
comparable to those of native human semilunar valve tissue
as to specific tensile strength (max. stress) and strain at
maximum load (max. strain) (stress-strain curves, see Figure
8). Compared with the static controls, the MSC-TEHV leaflets
were significantly stronger (max stress: 9212% versus
152% of native human valve tissue, P0.05) and less
pliable (Young’s modulus: 13914% versus 124% of
native human valve tissue, P0.05).
Discussion
As applied to the development of heart valve replacements,
tissue engineering merges aspects of cell biology and engi-
neering in an attempt to overcome the limitations of currently
available valve options, such as thromboembolism in me-
chanical prostheses and structural dysfunction in biological
heart valves.3–4 All clinically available valve substitutes
basically represent nonviable structures and lack the potential
to repair, to remodel, and to grow; the later imposing
substantial problems specifically to the pediatric cardiac
surgery patient population.5 The principal aim of heart valve
tissue engineering—that is in vitro fabrication of living heart
valves with a thromboresistant surface and a viable intersti-
tium—has been demonstrated by considerable experimental
work.6–11 Recently, our group reported the first successful
tissue engineering of a completely autologous and living
TEHV in a juvenile sheep model showing excellent func-
tional performance and strong resemblance to natural heart
valves as to morphological and biomechanical features.11
However, this and previous studies were based on the
utilization of vascular derived cells (VC) having the disad-
vantage to necessitate the sacrifice of intact vascular struc-
tures of the donor organism. Moreover, VC demonstrated
considerable differences compared with native valvular inter-
stitial cells, qualities which might be vital to the development
and long term function of TEHV.12
Given these problems it appeared that the ideal cell source
for TEHV is still undetermined. Therefore, we investigated
the feasibility to create functional TEHV on the basis of
MSC, which are known to exhibit traits of multipotent cells.
MSC can be routinely collected from patients, easily isolated
from human bone marrow, and can be induced in vitro to
differentiate into different mesenchymal cell types.13 In
addition, there is evidence that these cells have unique
immunological characteristics that allow persistence even in
an allogenic environment.14
Figure 5. Trichrome-masson staining of TEHV leaflets demon-
strated ECM and organized layered tissue formation with a
dense outer layer and less cellularity in the deeper portions (Fig.
5a). In contrast static controls showed less ECM deposition and
less organized tissue formation (Fig. 5b). Immunohistochemistry
showed the formation of collagen types I (Fig. 5c) and III (Fig.
5d) in the TEHV leaflet tips. Staining for ASMA (Fig. 5e) and
vimentin (Fig. 5f) revealed positive signals throughout the TEHV
leaflets.
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In the present study, isolation of the MSC was easy to
perform. Initial cell morphology appeared small and rounded
and cells started to grow in a colony-forming pattern followed
by myofibroblast-like cell development. Identical morpholog-
ical characteristics and growth pattern were described for
mesenchymal precursor cells by other studies using a com-
parable isolation procedure.15,16 Characterization of the MSC
populations before TEHV scaffold seeding revealed features
of myofibroblast-like differentiation such as expression of
ASMA, vimentin and the deposition of collagen types I and
III. A similar staining pattern was reported for human
valvular interstitial cells.17 Furthermore, desmin, CD 14, CD
31, and LDL were not detected indicating the absence of
myeloid and endothelial cell differentiation. Collagen type II
was also not observed, implying the absence of osteoblastoid
differentiation of the MSC.
In vitro exposure of tissue engineered cardiovascular cell
seeded constructs to biomimetic flow conditions has been
demonstrated to significantly enhance tissue maturation and
mechanical properties.11,18–19 Pulsatile flow or fluid dynamics
have a well known impact on cell morphology,20 prolifera-
tion,21 and composition of extracellular matrix.22 We previ-
ously reported application of an in vitro pulse duplicator
bioreactor system providing a gradually increasing flow and
pressure environment to grow completely autologous im-
plantable heart valves revealing the important impact of
biomimetic in vitro conditioning on tissue maturation.11
Based on this experience with vascular-derived cells, we
hypothesized that utilizing the pulse duplicator bioreactor to
grow TEHV constructs based on human MSC might guide
cell differentiation and tissue formation into the direction of
native heart valve tissue.
In fact, after tissue culture in the bioreactor for 14 days, the
MSC based valve constructs showed intact, mobile and
pliable leaflets and functional competence during valve clo-
sure even under supra-physiological flow and pressure con-
ditions. Histology of the TEHV leaflets revealed advanced
biodegradation of the scaffold replaced by a viable tissue
organized in a layered fashion with extracellular matrix
proteins characteristic of heart valve tissue such as collagen I
and III, and glycosaminoglycans. However, the typical three-
layered structural composition of native valve leaflets com-
prising a ventricularis, spongiosa, and fibrosa layer was not
achieved.23 ASMA positive cells expressing vimentin were
detectable throughout the constructs demonstrating
myofibroblast-like cell populations as described in native
semilunar valve tissue.17,24 Myeloid, osteoblastoid, and endo-
thelial cell differentiation of the isolated MSC was not
observed in the neo-tissue. There was no positive staining for
CD 14, collagen type II, CD 31, LDL, and desmin. The
Figure 6. TEM revealed actin/myosin filaments (focal densities, see arrow) typical of viable, secretionally active myofibroblasts as well
as collagen fibrils (#) and elastin fiber conglomerates (*, Figs. 6a and b). SEM of the TEHV demonstrated homogenous tissue and con-
fluent smooth surfaces with cell orientation in the direction of flow exposition (Fig. 6c), whereas the static controls showed a less con-
fluent, inhomogenous surface (Fig. 6d).
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ultra-structural analysis of the TEHV supported this observa-
tion demonstrating cell elements typical of viable, secretion-
ally active myofibroblasts such as actin/myosin filaments as
well as collagen fibrils and elastin.
The quantitative ECM protein analysis revealed values
significantly lower compared with human native valve tissue.
Concomitantly, the cell content was significantly increased,
possibly reflecting the high cellular turn-over of growing
tissue still in process to complete tissue development.
Whether this process of tissue remodeling and maturation
will be continuing under physiological conditions, as seen in
previous animal studies,11 needs to be determined in future
longer-term experiments. The histology of the valve con-
structs not exposed to pulsatile flow (static controls) showed
a loose, less organized tissue formation and SEM demon-
strated a less confluent and less homogeneous surface struc-
ture. Interestingly, there was no significant difference be-
tween the pulsed TEHV and the static controls as to the
quantitative ECM analysis. This may emphasize the fact, that
the biomimetic in vitro environment did not increase the
absolute amount of matrix protein formation but rather
influenced the degree of tissue organization and maturation.
This would be in accordance with the observation that the
mechanical properties of the controls showed significantly
weaker tissue properties as to the pulsed valve constructs.
Compared with native human semilunar heart valves the
mechanical evaluation of the pulsed MSC based TEHV
demonstrated a strong resemblance in the biomechanical
profiles, theoretically making these TEHV suitable for in vivo
implantation.
In summary, the present study demonstrated the feasibility
of creating functional TEHV on the basis of human MSC
utilizing a biomimetic in vitro culture environment. The
trileaflet TEHV showed mechanical properties and morpho-
logical features resembling native heart valves. MSC isola-
tion was easily performed without necessitating the sacrifice
of intact vascular structures. The MSC demonstrated charac-
teristics of myofibroblast differentiation showing their possi-
ble progenitor potential. It appears that human MSC represent
a promising cell source for cardiovascular tissue engineering
purposes, especially in regard to future routine clinical
application. However, these results are preliminary inasmuch
as this study was limited to in vitro experiments aiming
primarily at a proof of principle of this concept. Our next
efforts are directed at optimization of the MSC isolation
techniques as well as the in vitro culture conditions. Appli-
cation of growth factors, growth inhibitors and optimized
flow and pressure loading conditions will be areas of future
studies.
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